India's pharmaceutical company Cipla has launched the generic version of Remedisvir. The price of Ciprimi is 4,000 per 100 mg vial (vial), which is much lower than the medicines used for COVID-19 worldwide.
Cipremi is priced at Rs 4,000 per 100 mg vial, Cipla said in a statement according to healthworld.com.
"We are proud to commercially launch Cipremi today (on Wednesday); amongst the lowest priced globally, and aim to supply over 80,000 vials within the first month itself," Cipla Executive Vice-President and CEO (India Business) Nikhil Chopra said in an e-mailed statement.
To further ensure equitable distribution, the drug will be available through government and hospital channels only, he added.
"Cipla will also be donating some amount of the drug as part of its efforts to support the community in this time of need," Chopra said.
Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.